Andrew Abraham

andy-0101 My name in Andrew Abraham. I have been investing in commodities and managed futures since 1994. I adhere to the philosophy of trend following. Trend following stresses a disciplined approach to commodity/ futures trading. Successful trend following and commodity futures investing requires patience, discipline and actively managing the risk. What sets me apart from other traders is that I am not only concerned about the return on investment but how much risk I will have to tolerate to achieve my goals.

Contact Details

If you are interested in contacting for speaking engagements. Please email me at or call 954 903 0638.

Books Worth Reading

Sponsored Listings

Risk Warning

Futures and commodity trading involve substantial risk. The evaluations of futures and commodities may fluctuate and as a result, clients may lose more than their original investment. In no event should the content of this website be construed as an express or an implied promise, guarantee or implication by, that you will profit, or that losses can or will be limited in any manner whatsoever. Past results are no indication of future performance. Information provided on this website is intended solely for informative purposes and is obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible, where projections of future conditions are attempted.



Trend Following CTA abraham investment management
Binary Options
Learn Forex Trading Online
Get a grip on forex trading with this free online course.
Tax Software

High Growth Stock Investing Watch List $AGN $KORS

I am NOT recommending any stocks below for trading. I am building my own watch list based on my own criteria and in conjunction with CAN SLIM and High Growth Stock Investing. Past performance of stocks is not an indicative of future performance. Do your own research before investing on any of the stocks mentioned below.

Current Market
Unclear situation as the SPY is on a buy yet the QQQ which encompass many of our growth stocks is still on a sell. In this case I want confirmation from QQQ in order to start positions.


Stock Report Michael Kors

Michael Kors is one of the leading designers in the world today. My daughters have given the thumbs up cool.


However as we all know we are in a correction ( as of 5.4.2014). The buy point is 101.34. We are building a base.


Negatives are the group ranking and accumulation/distribution



Stock Pick # 2 Allergen
Allergen is the Queen of Botox. Many people want to look younger as well as there are other uses.
Some issues with earnings growth however AGN is on my watch list.
We’re So Vain: Botox Maker Is In High Demand
Posted by: Motif Investing on May 2, 2014 in Cultural Trends

We all know Botox, the popular anti-wrinkle drug that has become a regular treatment for the facially afflicted – and those that think they are – but do you know the company behind it?
Many health-care investors are undoubtedly a little more familiar with Allergan, the Irvine, California-based pharmaceutical company that has seen its stock rise about 37% in the last half of April alone after an unsolicited $45.7 billion takeover bid from Valeant Pharmaceuticals.
The stock’s rise has also had a big impact on the Vanity Flair motif, where Allergan shares have a 28.5% weighting. The motif has gained 10.2% in the past month. In that same period, the S&P 500 is up 0.5%.
(In the past 12 months, the motif has risen 22.8%; the S&P 500 has increased 20.4%.)

Fortunately, at least for Allergan shareholders, the simple takeover bid by Valeant hasn’t been so simple, if only because Allergan has been playing hard to get. Since the news of Valeant’s offer was reported, news reports have come forth that Allergan has a) considered its own purchase of Shire Pharmaceuticals in order to make itself more difficult to acquire by Valeant; b) sought out companies like Sanofi and Johnson & Johnson to see if they would have interest in a richer bid; and c) watched as investment banks reached out to German manufacturer Bayer to see if that company had interest.1
All of which goes to suggest that if Allergan goes, it does not want to go cheaply.
On the surface, the attractiveness of Allergan isn’t much of a secret. As Bloomberg News pointed out, the company’s sales are projected by analysts to grow every year, reaching $9 billion in 2018, up from $6.3 billion in 2013, with Botox remaining as the company’s crown jewel.
Within that $6.3 billion, of course, are a whole lot of trips to plastic surgeons, with even more to come. The American Association of Plastic Surgeons reported that The American Association of Plastic Surgeons reported that its members performed more than 6.3 million botulinum toxin injections (Botox and other drugs) for wrinkle reduction in 2013, making this the most popular non-invasive cosmetic procedure.2
And the market for cosmetic procedures continues to grow, showing a 3% increase over the previous year.
The second-most popular procedure is a so-called soft-tissue filler, a procedure which fills in facial folds to build fullness. Last year, there were 2.2 million procedures performed, a 13% increase over 2012. And guess which product is the market leader? Juvéderm, made by – you guessed it – Allergan.
As Beth Nichols wrote at The Motley Fool, this field of medical aesthetics is a significant category for drug companies because procedures are almost exclusively paid for out-of-pocket, bypassing health insurance and the cost-trimming realities of managed care. The average cost for Botox injections nationwide is about $500. The effect will usually last three to six months, potentially giving the product a strong base of repeat customers.
However, an even bigger part of the future for Botox may be its expanded medical use. Today, Botox revenues are split down the middle between aesthetic indications and therapeutic indications. However, therapeutic is the big growth driver as new indications could lead to doubling in the sales of the overall franchise by 2020, according to TheStreet.3
Already, Botox is used to treat chronic migraine (US approval in 2010), neurogenic overactive bladder (US approval 2011), idiopathic overactive bladder (approved in Jan 2013). But many other indications are underway, including BPH and osteoarthritis, as well as depression.
Allergan’s story, however, could be an instructive one for investors who are initially attracted to aesthetic side of the business, especially if growth in more traditional medical uses proves to be the company’s better side.
1David Welch, Matthew Campbell and Jeffrey McCracken, “Allergan Exploring Sale to Sanofi, J&J,”, April 29, 2014,
2Beth Nichols, “Why Valeant International Inc. Is Acquiring Botox and Juvederm Maker Allergan,”, April 23, 2014,, (accessed April 30, 2014).

Be Sociable, Share!
Add This! Blinkbits Blinklist Blogmarks BlogMemes BlueDot BlogLines co.mments Connotea Digg Diigo DZone Facebook FeedMeLinks Fleck Furl Google Google Reader IndianPad Leonaut LinkaGoGo Linkarena Linkter Magnolia Mister Wong MyShare MyStuff Yahoo! MyWeb Netscape Netvouz Newsgator Newsvine RawSugar reddit Rojo Segnalo Shadows Simpy SlashDot Smarking Sphere Spurl Startaid StumbleUpon TailRank Technorati ThisNext Plugin by

Leave a Reply




You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>